Number of Patients Who Developed Neutralizing Antibodies After One or More Cycles of BL22 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]Fresh malignant cells are isolated from blood, bone marrow, lymph nodes or other tissue and incubated with recombinant immunotoxins to determine sensitivity to BL22 and other agents to estimate the amount of cancer cells in the body by measuring prote